{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:16:46Z","timestamp":1782447406069,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304297"],"award-info":[{"award-number":["82304297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22077018"],"award-info":[{"award-number":["22077018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.apsb.2025.06.016","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T02:50:36Z","timestamp":1750733436000},"page":"4115-4136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bioisosterism-driven design of orally active, safe, and broad-spectrum biphenyl-DAPY derivatives as highly potent HIV-1 non-nucleoside reverse transcriptase inhibitors"],"prefix":"10.1016","volume":"15","author":[{"given":"Xiao-Mei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qing","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen-Er","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.06.016_bib1","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1039\/c2cs35058k","article-title":"In search of a treatment for HIV-current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs)","volume":"41","author":"Reynolds","year":"2012","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2025.06.016_bib2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2174\/1381612024607207","article-title":"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives","volume":"8","author":"Campiani","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.apsb.2025.06.016_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.108261","article-title":"Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety","volume":"34","author":"Zhao","year":"2023","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2025.06.016_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.apsb.2025.06.016_bib5","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","article-title":"Approved HIV reverse transcriptase inhibitors in the past decade","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.016_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.07.006","article-title":"Linker optimization of HEPT derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors: from S=O to CHOR","volume":"34","author":"Hao","year":"2023","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2025.06.016_bib7","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1021\/acs.jmedchem.3c00275","volume":"66","author":"Wang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib8","doi-asserted-by":"crossref","first-page":"13604","DOI":"10.1021\/acs.jmedchem.1c00987","article-title":"Structure-based design and discovery of pyridyl-bearing fused bicyclic HIV-1 inhibitors: synthesis, biological characterization, and molecular modeling studies","volume":"64","author":"Huang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejmech.2018.09.013","article-title":"Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors","volume":"158","author":"Gu","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/med.21760","article-title":"Druggability modification strategies of the diarylpyrimidine-type non-nucleoside reverse transcriptase inhibitors","volume":"41","author":"Ding","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2025.06.016_bib11","doi-asserted-by":"crossref","first-page":"17568","DOI":"10.1021\/acs.jmedchem.4c01571","article-title":"Fragment addition-based design of heteroaromatic-biphenyl-DAPYs as potent and orally available non-nucleoside reverse transcriptase Inhibitors featuring significantly enhanced safety","volume":"67","author":"Huang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib12","doi-asserted-by":"crossref","first-page":"13658","DOI":"10.1021\/acs.jmedchem.1c01015","article-title":"Discovery of novel dihydrothiopyrano[4,3-d]pyrimidine derivatives as potent HIV-1 NNRTIs with significantly reduced hERG inhibitory activity and improved resistance profiles","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib13","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1021\/acs.jmedchem.0c00117","article-title":"Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties","volume":"63","author":"Kang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/13543776.2017.1303046","article-title":"Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1","volume":"27","author":"Kang","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2025.06.016_bib15","doi-asserted-by":"crossref","first-page":"10297","DOI":"10.1021\/acs.jmedchem.1c00708","article-title":"Improving druggability of novel diarylpyrimidine NNRTIs by a fragment-based replacement strategy: from biphenyl-DAPYs to heteroaromatic-biphenyl-DAPYs","volume":"64","author":"Ding","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.016_bib17","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1016\/j.bmc.2010.05.036","article-title":"Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors","volume":"18","author":"Liang","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib18","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1016\/j.bmc.2015.03.037","article-title":"Anti-HIV diarylpyrimidine\u2013quinolone hybrids and their mode of action","volume":"23","author":"Mao","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ejmech.2018.01.016","article-title":"Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1","volume":"145","author":"Jin","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib20","doi-asserted-by":"crossref","first-page":"11430","DOI":"10.1021\/acs.jmedchem.9b01446","article-title":"Ligand-based design of nondimethylphenyl-diarylpyrimidines with improved metabolic stability, safety, and oral pharmacokinetic profiles","volume":"62","author":"Sang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib21","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1021\/acs.jmedchem.1c00128","article-title":"Hydrophobic pocket occupation design of difluoro-biphenyl-diarylpyrimidines as non-nucleoside HIV-1 reverse transcriptase inhibitors: from N-alkylation to methyl hopping on the pyrimidine ring","volume":"64","author":"Ding","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/138945010790711996","article-title":"Halogen atoms in the modern medicinal chemistry: hints for the drug design","volume":"11","author":"Hernandes","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.apsb.2025.06.016_bib23","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3390\/molecules27051643","article-title":"New halogen-containing drugs approved by FDA in 2021: an overview on their syntheses and pharmaceutical use","volume":"27","author":"Benedetto Tiz","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.06.016_bib24","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.1021\/acs.jmedchem.8b01453","article-title":"Halogens in protein-ligand binding mechanism: a structural perspective","volume":"62","author":"Shinada","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib25","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.apsb.2023.11.021","article-title":"Late-stage modification of bioactive compounds: improving druggability through efficient molecular editing","volume":"14","author":"Huo","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.016_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14756360701425014","article-title":"The role of fluorine in medicinal chemistry","volume":"22","author":"Shah","year":"2007","journal-title":"J Enzym Inhib Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib27","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115586","article-title":"Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023","volume":"258","author":"Han","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.pharmtox.41.1.443","article-title":"Metabolism of fluorine-containing drugs","volume":"41","author":"Park","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.apsb.2025.06.016_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1039\/B610213C","article-title":"Fluorine in medicinal chemistry","volume":"37","author":"Purser","year":"2008","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2025.06.016_bib31","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib32","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1021\/acs.jmedchem.2c02015","article-title":"\"Magic Chloro\": profound effects of the chlorine atom in drug discovery","volume":"66","author":"Chiodi","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib33","first-page":"75","article-title":"Robust NHC-palladacycles-catalyzed Suzuki\u2212Miyaura cross-coupling of amides via C\u2013N activation","volume":"1","author":"Deng","year":"2020","journal-title":"Green Synth Catal"},{"key":"10.1016\/j.apsb.2025.06.016_bib34","first-page":"110","article-title":"Palladium-catalyzed sulfonylative coupling of benzyl(allyl) carbonates with arylsulfonyl hydrazides","volume":"3","author":"Gong","year":"2022","journal-title":"Green Synth Catal"},{"key":"10.1016\/j.apsb.2025.06.016_bib35","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ejmech.2006.11.014","article-title":"Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains","volume":"42","author":"Mordant","year":"2007","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib36","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1016\/j.apsb.2023.07.008","article-title":"Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility","volume":"13","author":"Zhao","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.016_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s42004-023-00888-4","article-title":"Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors","volume":"6","author":"Jiang","year":"2023","journal-title":"Commun Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib38","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21445","article-title":"Development of safe drugs: the hERG challenge","volume":"38","author":"Kalyaanamoorthy","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2025.06.016_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib40","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.016_bib41","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1080\/03639045.2017.1371732","article-title":"Enhancement of oral bioavailability of anti-HIV drug rilpivirine HCl through nanosponge formulation","volume":"43","author":"Zainuddin","year":"2017","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.apsb.2025.06.016_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113678","article-title":"Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis","volume":"223","author":"Du","year":"2021","journal-title":"Eur J Med Chem"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525004368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525004368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T17:03:02Z","timestamp":1755622982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525004368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2211383525004368"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.06.016","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioisosterism-driven design of orally active, safe, and broad-spectrum biphenyl-DAPY derivatives as highly potent HIV-1 non-nucleoside reverse transcriptase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}